This site is intended for health professionals only
Sunday 16 June 2019
Share |

Topic: clinical trial

December 1, 2017
Combining two different immunotherapy treatments could dramatically improve lymphoma survival, according to a Cancer Research UK funded study published in Cancer Cell

Researchers from the University of Southampton have tested different combinations of antibodies in the lab to see how they interact with each other and what effect this has on how the immune system fights cancer.


They found one combination – anti-CD27 and anti-CD20 – greatly increased life expectancy in mice with cancer. While most of the mice given just one of the antibodies died within 80 days, nearly all mice given both antibodies survived beyond 100 days.

September 19, 2016
FRAME data simultaneously published in New England Journal of Medicine and presented at ASBMR showed treatment with romosozumab significantly reduced new vertebral and clinical fractures in postmenopausal osteoporosis

UCB has announced findings from the FRAME study showing that the investigational agent romosozumab significantly reduced the incidence of new vertebral fractures in postmenopausal women with osteoporosis through 12 and 24 months, meeting the study’s co-primary endpoints.

 

February 2, 2016
Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza for the treatment of chronic hepatitis C (HCV) in three new patient populations

Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza for the treatment of chronic hepatitis C (HCV) in three new patient populations. The expanded label allows for the use of Daklinza in combination with sofosbuvir (with or without ribavirin, depending on the indication and HCV genotype) in HCV patients with decompensated cirrhosis, HIV-1 (human immunodeficiency virus) co-infection, and post-liver transplant recurrence of HCV in all 28 Member States of the European Union.

 

March 11, 2015
New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.

New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.
 

 

October 29, 2014
Interim results from one of the largest and longest clinical trials ever conducted for a topical treatment in psoriasis* showed that after eight weeks of treatment with calcipotriol/betamethasone dipropionate (Daivobet® gel), the treatment was highly efficacious, preferred by patients and improved patients' and the physicians’ assessments of disease severity.

Interim results from one of the largest and longest clinical trials ever conducted for a topical treatment in psoriasis* showed that after eight weeks of treatment with calcipotriol/betamethasone dipropionate (Daivobet® gel), the treatment was highly efficacious, preferred by patients and improved patients' and the physicians’ assessments of disease severity. (1)

September 5, 2014
Celgene Corporation announced that data from FIRST (MM-020/IFM 07-01)—an open-label phase III randomised study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant— have been published in the Sept. 4 issue of the New England Journal of Medicine.

Celgene Corporation announced that data from FIRST (MM-020/IFM 07-01)—an open-label phase III randomised study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant— have been published in the Sept. 4 issue of the New England Journal of Medicine.

February 10, 2010
British biotech company ReNeuron has been given the green light to start a clinical trial to treat stroke patients with stem cells

teaser

December 5, 2008
Clinical trial shows prostrate cancer drug causes testosterone levels to fall dramatically

teaser

November 13, 2008
Results from drug trial leave questions unanswered as vaccine fails to protect against HIV

teaser

November 11, 2008
Bayer

teaser

November 10, 2008
Great success of cholesterol-lowering drug leads to an early end of a clinical trial

teaser

October 17, 2008
Innovative clinical trial and transplant registry link produces long-term follow up data

teaser

September 19, 2008
Ustekinumab demonstrates superior efficacy to Enbrel in moderate to severe plaque psoriasis

teaser

February 26, 2008
Pharmaceutical giant Ipsen has revealed the first results of a phase III study evaluating the safety of Acapodene (toremifene citrate) in advanced prostate cancer patients

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine